Minimize

Welcome!

Theralase Demonstrates Stability of Lead Drug

September 4, 2015

Toronto, Ontario (FSCwire)Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has demonstrated initial stability of its lead Photo Dynamic Compound (“PDC”), TLD-1433, currently being developed by the Company for the treatment of Non-Muscle Invasive Bladder Cancer (“NMIBC”).

Demonstrating long term and accelerated stability of a drug to be used in human clinical testing is essential to prove that the potency and/or efficacy of the drug is not affected during prolonged shelf life.

Under long term and accelerated stability storage conditions, the drug is evaluated by High Performance Liquid Chromatography (“HPLC”) to separate, identify and quantify each chemical component to a very high degree of resolution to assess if any changes occur in the chemical composition over time.

Long term stability is completed over three years, with reporting at 0, 3, 6, 9, 12, 18, 24 and 36 months. Accelerated stability is completed over six months, with reporting at 0, 3 and 6 months.

The data collected at three months represent the first reporting period under long term stability and the mid-way point under accelerated stability. TLD-1433 has clearly demonstrated that it has remained stable at these reported time periods. According to Health Canada guidelines, long term and accelerated stability must be demonstrated at 6 months to commence treating patients in a clinical study.

Roger Dumoulin-White, President and CEO, Theralase stated that, “Theralase has shown that TLD-1433, being developed for NMIBC, has passed another hurdle on its way to being evaluated clinically. The Company is confident that TLD-1433 will remain stable over the next 3 months, allowing Theralase the opportunity to get one step closer to proving its primary objective of safety and tolerability, and an exploratory objective of efficacy, in cancer patients afflicted with NMIBC, in a Phase Ib human trial scheduled to commence in late 4Q2015.”

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com .

Theralase Technologies Inc. was recognized as a TSX Venture 50® company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.

This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

 

For More Information:

Michael Borovec

Director of Investor Relations

1.866.THE.LASE (843-5273) ext. 222

416.699.LASE (5273) ext. 222

mborovec@theralase.com

www.theralase.com

Discussion
7 Comments
    CFS
    Sep 04, 2015 04:24 AM

    A bit Off-Topic.
    I was listening to the UK 6 p.m. news……
    The National Health Service, facing money problems, is now cutting about half of all cutting-edge anti-cancer drugs from availability, because they are not “cost-effective.
    The problem with the UK national health service is that a wealthy person cannot offer to pay for drugs. The only option is to go totally private, outside of the NHS if you want access to drugs that are not available on the NHS.
    Just wait for the Obamacare system to degrade US health care. I worry that it will also destroy development of new drugs.

      Sep 04, 2015 04:23 AM

      It’s just one more little step towards offering the lethal injection instead, so called assisted suicide, assisted by the government of course.

      Sep 05, 2015 05:42 PM

      CFS, it doesn’t sound like you are aware of the work Theralase is doing. See my coments below.

    Sep 04, 2015 04:25 AM

    Actually CFS, your comment was bang on topic.

    Sep 04, 2015 04:29 AM

    We need to hope and pray that the onward progress of private enterprise technology is sufficient to compensate for the regression caused by governments failings.

    I don’t believe in all that ‘singulaity’ hype nonsense that pseudo-scientists and promoters spout by the way. Technological development is in retreat on the macro level and is already confined to low energy usage technology areas.

    I think that quite possibly we are reaching a different turning point, where the march of technology and increasing productivity is insufficient to compensate for the heavy weight of government. That is a turning point in civilisation.

    Sep 04, 2015 04:32 AM

    Technology peaked when man stood on the moon and Viking and Voyagers 1&2 were launched. Period. Chris Martenson had better get on the case of peak technology, never mind peak oil, though the two may be related!

    Sep 05, 2015 05:35 PM

    Current so called”cutting edge cancer drugs , including those in use and those in development,” are not very effective clinical treatments” How do any of them compare with the pre clinical results of Theralase TLD-1433, with a tumor destruction of 98%, with no toxic side effects and with zero reocurance of the cancer after 1 yr ?
    The Theralase TLD-1433 will most likely prove to be this safe and this efficient in humans because the procedure is more akin to a medical device than to a drug.